Carlsbad, CA (PRWEB) November 14, 2016
A recently published white paper from The Center for Advanced Breast Care in Arlington Heights, IL, reports the CMR Naviscan’s Solo II High Resolution Breast PET scanner to be an effective tool in managing care for its patients.
The white paper summarizes the initial retrospective analysis of 130 patients, reporting a false positive rate of 1%. Imaging of the axilla is gaining increased attention in the management of breast cancer patients as axillary lymph node can be a critical prognostic indicator. The findings point to CMR Naviscan Breast PET imaging as possibly being a more effective tool than other means, including physical exam, ultrasound or Breast MRI. Due to the high specificity and low false positive rate findings in the initial evaluation, Breast PET could play a crucial role in the pre-surgical assessment of the axilla in patients diagnosed with breast cancer.
Dr. Michael Kinney, Director of The Center for Advanced Breast Care, and lead author of the study, reports “that High Resolution Breast PET imaging enhances patient care by identifying the extent of disease in the breast and axilla. Metabolic information provided by high resolution Breast PET could play a major role in guiding the preoperative investigation, to include decision regarding neoadjuvant chemotherapy and the use of sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND).”
For a full copy of the clinical study white paper go to the CMR Naviscan website.
About CMR Naviscan
CMR Naviscan is a leader in organ-specific molecular imaging and part of the Compañía Mexicana de Radiología CGR, S.A. de C.V. (CMR) family of companies. CMR is a major developer and manufacturer of high quality diagnostic imaging equipment that contributes to healthcare improvements through a technological innovation framework. This includes the conversion, storage, processing and distribution of diagnostic imaging in digital form. CMR Naviscan is headquartered in Carlsbad, California, is US FDA registered and ISO 13485:2012 certified. Our flag ship product, the Solo II™ High Resolution Breast PET scanner, detects breast cancers as small as 1.6 mm. Solo II is the industry leader in terms of its sensitivity and specificity in characterizing the extent and location(s) of previously diagnosed breast cancers.